Equity Profile

BBIO

BridgeBio Pharma, Inc.

Health CareBiotechnology$15.9B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-0.57

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$220M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases. With a market cap of $16 billion, it plays a significant role in the health care sector, particularly in addressing rare and complex conditions through innovative treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1 2026, BridgeBio reported an EPS of $-0.84, missing estimates by 19%. The stock reacted negatively, dropping 0.94% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect BridgeBio to report a loss of $-0.57 per share on $220 million in revenue for Q2 2026. The company has a mixed earnings history, which adds uncertainty to these expectations.

Bull Case

If BridgeBio can exceed the EPS estimate and show strong revenue growth, it may signal improved demand for its therapies and boost investor confidence.

Bear Case

Conversely, if the company misses expectations again, it could raise concerns about its product pipeline and overall financial health, leading to a negative stock reaction.

Key Metrics to Watch

EPS

$-0.57

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$220M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.57?

A better-than-expected EPS could indicate improved operational efficiency and market demand, potentially boosting investor confidence.

What are the revenue figures compared to the expected $220 million?

Revenue performance is crucial for understanding the company's market traction and future growth potential, which will heavily influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate BridgeBio's potential for a turnaround, as recent product developments could lead to higher-than-expected demand.

Supporting Evidence

The company has a history of surprising on the upside, with a 12% beat rate in previous quarters.

Recent insider buying suggests confidence in the company's future prospects, which may not be reflected in current consensus estimates.

Key Risk

If the company reports revenue significantly above $236 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results are pivotal as they will either reinforce or challenge the market's current perceptions of BridgeBio's growth and profitability.

Bull Confirmed If

An EPS of $-0.50 or better, along with revenue exceeding $230 million, would confirm a strong recovery and growth outlook.

Bear Confirmed If

An EPS worse than $-0.71 and revenue below $208 million would signal ongoing struggles and could lead to a significant sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±1.75%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a modest move of about 1.75% following the earnings report, indicating some uncertainty but not extreme volatility.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests a potential stock increase of around 1.48%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions, reflecting cautious investor sentiment.

Miss

A miss on earnings could lead to a decline of about 1.48%, as seen in past quarters, raising concerns about the company's future.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management and operational efficiency improvements.
4Guidance on future revenue expectations and market strategies.
5Responses to analyst questions regarding regulatory developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-0.57

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$220M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1 2026, BridgeBio reported an EPS of $-0.84, missing estimates by 19%. The stock reacted negatively, dropping 0.94% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect BridgeBio to report a loss of $-0.57 per share on $220 million in revenue for Q2 2026. The company has a mixed earnings history, which adds uncertainty to these expectations.

Bull Case

If BridgeBio can exceed the EPS estimate and show strong revenue growth, it may signal improved demand for its therapies and boost investor confidence.

Bear Case

Conversely, if the company misses expectations again, it could raise concerns about its product pipeline and overall financial health, leading to a negative stock reaction.

Key Metrics to Watch

EPS

$-0.57

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$220M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.57?

A better-than-expected EPS could indicate improved operational efficiency and market demand, potentially boosting investor confidence.

What are the revenue figures compared to the expected $220 million?

Revenue performance is crucial for understanding the company's market traction and future growth potential, which will heavily influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate BridgeBio's potential for a turnaround, as recent product developments could lead to higher-than-expected demand.

Supporting Evidence

The company has a history of surprising on the upside, with a 12% beat rate in previous quarters.

Recent insider buying suggests confidence in the company's future prospects, which may not be reflected in current consensus estimates.

Key Risk

If the company reports revenue significantly above $236 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results are pivotal as they will either reinforce or challenge the market's current perceptions of BridgeBio's growth and profitability.

Bull Confirmed If

An EPS of $-0.50 or better, along with revenue exceeding $230 million, would confirm a strong recovery and growth outlook.

Bear Confirmed If

An EPS worse than $-0.71 and revenue below $208 million would signal ongoing struggles and could lead to a significant sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±1.75%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a modest move of about 1.75% following the earnings report, indicating some uncertainty but not extreme volatility.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests a potential stock increase of around 1.48%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions, reflecting cautious investor sentiment.

Miss

A miss on earnings could lead to a decline of about 1.48%, as seen in past quarters, raising concerns about the company's future.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management and operational efficiency improvements.
4Guidance on future revenue expectations and market strategies.
5Responses to analyst questions regarding regulatory developments.